Navigation Links
Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Date:3/17/2008

Potential to Develop Disease Treatments for Diabetic Kidney Disease and

Retinopathy, Each Multi-Billion-Dollar Drug Markets

JENKINTOWN, Pa., March 17 /PRNewswire/ -- Dynamis Therapeutics, Inc. announced the discovery of a new class of compounds that inhibit the production of RAGE, the Receptor for Advanced Glycation End Products (AGEs). Scientists expect that a RAGE inhibitor would be an important addition to the arsenal of drugs to treat diabetic kidney disease, retinopathy, microvascular disease, Alzheimer's, inflammatory diseases, some cancers, and aging.

A patent has been filed on the discovery.

A team of Dynamis Therapeutics' scientists significantly decreased kidney and retina RAGE in aged rats that were orally dosed with Dynamis Therapeutics' RAGE inhibitor for 32 weeks, as compared to non-treated rats. In addition, several other new compounds also inhibited RAGE in a variety of cells grown in culture.

In a parallel experiment, Dynamis Therapeutics' scientists increased the life span of mice by adding a RAGE inhibitor to their drinking water. The laboratory mice were divided into four groups: a control group treated only with water and three groups treated with varying doses of the RAGE inhibitor. The mice receiving the highest RAGE inhibitor dose lived, on average, 256 days longer than those receiving only water. Longevity increased proportionally with dosage strength.

Commented Dr. Annette Tobia, president and founder of Dynamis Therapeutics, Inc., "We are very excited about these results, since discovering RAGE inhibitors enables Dynamis Therapeutics to develop a treatment for diabetic kidney disease and blindness. Diabetes and its complications have become epidemic, not only in the United States, but worldwide. Retinopathy often leads to blindness. It would be a tremendous advance to eventually have a drug to treat such a serious disease."

Dynamis Therapeutics, Inc., located in Jenkintown, Pennsylvania (http://www.dynamis-therapeutics.com), develops products that treat chronic inflammatory conditions and accelerated aging diseases such as diabetic nephropathy and retinopathy.

Dynamis Therapeutics supports its research, in part, by marketing the MEG 21 product line of anti-aging and anti-wrinkling cosmetic skin care products to dermatologists, plastic surgeons, and aestheticians and by out-licensing the cosmetic applications of its breakthrough technology for fees and royalties.

Dynamis Therapeutics' technology is based on the discovery of an aging/inflammatory pathway that was made by its scientific founders while they were working at the Fox Chase Cancer Center in Philadelphia. The technology is exclusively licensed to Dynamis Therapeutics. Dynamis Therapeutics is presently preparing to file an IND with the FDA for a treatment for inflammation associated with dry eye.


'/>"/>
SOURCE Dynamis Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
2. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
3. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
4. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
7. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
8. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
9. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
10. Video: New Research Discovers Independent Brain Networks Control Human Walking
11. National Stem Cell Holding, Inc. Discovers Non-Embryonic Biomaterials that Promote Tissue Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):